Stock,
Star Health and Allied Insurance (Star Health), a stock in Rekha Jhunjhunwala’s portfolio, has a ‘Buy’ rating and a one-year target price. 700. This suggests that the insurance stock could rise by 33% from its current market price.
The private health insurer’s shares ended the day down 1.73 percent. 517.90 per share during trading on Friday. The stock has declined 23% over the most recent one year time span.
Motilal Oswal emphasized in a note that Star Health is concentrating on a profitable product mix through an increase in the share of specialty products, the processing of claims through network hospitals, an emphasis on profitable banka products, and value addition.
Individual agents will continue to make up 82% of Star Health, but distribution channels like banka (5%) and digital (9%), whose combined share will rise to 20% in 3-5 years, will grow at a relatively faster rate.
Star Health will benefit from the recently announced Expenses under Management (EoM) regulation because the majority of the competition operates significantly below the 35%/3% threshold for SAHI/GI players.
The company intends to link the payout mechanism to the loss ratio of each agent in the future in order to maximize commission payments to agents on the back-book. New business and backbook rates may also differ.
Star Health is of the opinion that life insurance (LI) players cannot provide banca customers with a better value proposition than general insurance (GI) players.
Through a partnership with Fintech companies, Star Health will soon enter the premium financing market without taking any risks to their balance sheet.
Additionally, Anand Rathi has initiated coverage on Star Health with a target price of 723, implying a 40 percent upside.
The opinions and suggestions presented above are those of individual analysts or brokerage firms and not those of o2help.
